2.72
0.00 (0.00%)
Previous Close | 2.72 |
Open | 2.72 |
Volume | 3,441 |
52 Weeks Range |
Profit Margin | -200.30% |
Operating Margin (TTM) | 46.22% |
Quarterly Revenue Growth (YOY) | 4,399.70% |
Quarterly Earnings Growth (YOY) | -65.50% |
Current Ratio (MRQ) | 0.240 |
Operating Cash Flow (TTM) | -310.18 M |
Levered Free Cash Flow (TTM) | -287.74 M |
Return on Assets (TTM) | -7.61% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
Stock | Alvotech Warrant | - | - |
Stockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | NA |
Technical Moving Averages | 0.0 |
Technical Oscillators | 0.0 |
Average | 0.00 |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Ownership
Name | Date | Shares Held |
---|---|---|
Linden Advisors Lp | 30 Jun 2024 | 273,380 |
Arena Capital Advisors, Llc- Ca | 30 Jun 2024 | 60,714 |
Moore Capital Management, Lp | 30 Jun 2024 | 50,000 |
Sculptor Capital Lp | 30 Jun 2024 | 49,939 |
Freegulliver Llc | 30 Jun 2024 | 43,681 |
Boussard & Gavaudan Investment Management Llp | 30 Jun 2024 | 30,000 |
Kim, Llc | 30 Jun 2024 | 15,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |